April 2, 2013
Mitsubishi Tanabe Pharma Corporation (MTPC) announced on April 1 that its licensee Janssen Pharmaceuticals of the US (New Jersey) obtained approval from the US FDA for the sodium glucose co-transporter-2 (SGLT-2) inhibitor canagliflozin (development code: TA-7284) on March 29 (local...read more